TAICHUNG, November 09, 2021 / -- Alar Pharmaceuticals Inc. (6785.TWO) announced the positive results of single-ascending-dose study assessing safety, tolerability, and pharmacokinetics of ALA-1000 in opioid dependent patients. A total of 59 patients were enrolled in the study conducted at a single clinical center in the US. 46 subjects met the completer criteria for the 27-week study period. All drug-related AEs were mild or moderate in…
Alar Pharmaceuticals Inc. (abbreviated as Alar Pharm), a new drug development company focused on long-acting release drug products, has announced that it concluded its End-of-Phase 2 (EOP2) meeting with U.S. Food and Drug Administration (FDA) for ALA-1000 on October 27, 2021. ALA-1000 is a long-acting new drug under development to treat opioid use disorder (OUD) with a particular dosing interval of subcutaneous injection once every three months. Based on the…
